COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper

Martin Rakusa¹, Serefnur Öztürk², Elena Moro³, Raimund Helbok^{4

5}, Claudio L Bassetti⁵, Ettore Beghi⁶, Daniel Bereczki⁷, Benedetta Bodini^{8

9}, Giovanni Di Liberto¹⁰, Thomas M Jenkins^{11

12}, Antonella Macerollo^{13

14}, Luis F Maia^{15

16}, Filippo Martinelli-Boneschi^{17

18}, Antonio Pisani^{19

20}, Alberto Priori²¹, Anna Sauerbier²², Riccardo Soffietti²³, Pille Taba^{24

25}, Tim J von Oertzen^{26

27}, Marialuisa Zedde²⁸, Michael Crean²⁹, Anja Burlica²⁹, Francesco Cavallieri^{28

30}, Johann Sellner³¹; European Academy of Neurology NeuroCOVID-19 Task Force

Affiliations

¹ Department of Neurologic Diseases, Maribor University Medical Center, Maribor, Slovenia.
² Department of Neurology and Neurointensive Care, Selcuk University Faculty of Medicine, Konya, Turkey.
³ Division of Neurology, University Hospital Center of Grenoble, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.
⁴ Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
⁵ Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
⁶ Mario Negri Institute of Pharmacological Research, Scientific Institute for Research and Health Care, Milan, Italy.
⁷ Department of Neurology, Semmelweis University, Budapest, Hungary.
⁸ Department of Neurology, Saint Antoine Hospital, Public Hospital Network of Paris, Paris, France.
⁹ Paris Brain Institute, Sorbonne University, Paris, France.
¹⁰ Department of Clinical Neurosciences, Vaudois University Hospital Center and University of Lausanne, Lausanne, Switzerland.
¹¹ Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
¹² Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK.
¹³ Walton Centre National Health Service Foundation Trust for Neurology and Neurosurgery, Liverpool, UK.
¹⁴ Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.
¹⁵ Department of Neurology, Saint Antonio Hospital, Porto University Hospital Center, Porto, Portugal.
¹⁶ Institute of Research and Innovation in Health, University of Porto, Porto, Portugal.
¹⁷ Neurology Unit and Multiple Sclerosis Center, Ca' Granda Ospedale Maggiore Hospital Polyclinic, Scientific Institute for Research and Health Care Foundation, Milan, Italy.
¹⁸ Department of Pathophysiology and Transplantation, Dino Ferrari Center, Neuroscience Section, University of Milan, Milan, Italy.
¹⁹ Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
²⁰ Mondino Foundation, Scientific Institute for Research and Health Care, Pavia, Italy.
²¹ Division of Neurology, Department of Neurology, Aldo Ravelli Research Center, University of Milan and ASST Saints Paul and Charles, Milan, Italy.
²² Department of Neurology, Faculty of Medicine and Cologne University Hospital, University of Cologne, Cologne, Germany.
²³ Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy.
²⁴ Department of Neurology and Neurosurgery, Institute of Clinical Medicine, Tartu, Estonia.
²⁵ Tartu University Hospital, Tartu, Estonia.
²⁶ Department of Neurology, Neuromed Campus, Kepler University Hospital, Linz, Austria.
²⁷ Medical Faculty, Johannes Kepler University, Linz, Austria.
²⁸ Neurology Unit, Neuromotor and Rehabilitation Department, USL-IRCCS Company of Reggio Emilia, Reggio Emilia, Italy.
²⁹ European Academy of Neurology Head Office, Vienna, Austria.
³⁰ Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
³¹ Department of Neurology, Mistelbach-Gänserndorf State Hospital, Mistelbach, Austria.

PMID: 35460319
PMCID: PMC9111566
DOI: 10.1111/ene.15368

COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper

Martin Rakusa et al. Eur J Neurol. 2022 Aug.

. 2022 Aug;29(8):2163-2172.

doi: 10.1111/ene.15368. Epub 2022 May 10.

Authors

Affiliations

¹ Department of Neurologic Diseases, Maribor University Medical Center, Maribor, Slovenia.
² Department of Neurology and Neurointensive Care, Selcuk University Faculty of Medicine, Konya, Turkey.
³ Division of Neurology, University Hospital Center of Grenoble, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.
⁴ Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
⁵ Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
⁶ Mario Negri Institute of Pharmacological Research, Scientific Institute for Research and Health Care, Milan, Italy.
⁷ Department of Neurology, Semmelweis University, Budapest, Hungary.
⁸ Department of Neurology, Saint Antoine Hospital, Public Hospital Network of Paris, Paris, France.
⁹ Paris Brain Institute, Sorbonne University, Paris, France.
¹⁰ Department of Clinical Neurosciences, Vaudois University Hospital Center and University of Lausanne, Lausanne, Switzerland.
¹¹ Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
¹² Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK.
¹³ Walton Centre National Health Service Foundation Trust for Neurology and Neurosurgery, Liverpool, UK.
¹⁴ Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.
¹⁵ Department of Neurology, Saint Antonio Hospital, Porto University Hospital Center, Porto, Portugal.
¹⁶ Institute of Research and Innovation in Health, University of Porto, Porto, Portugal.
¹⁷ Neurology Unit and Multiple Sclerosis Center, Ca' Granda Ospedale Maggiore Hospital Polyclinic, Scientific Institute for Research and Health Care Foundation, Milan, Italy.
¹⁸ Department of Pathophysiology and Transplantation, Dino Ferrari Center, Neuroscience Section, University of Milan, Milan, Italy.
¹⁹ Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
²⁰ Mondino Foundation, Scientific Institute for Research and Health Care, Pavia, Italy.
²¹ Division of Neurology, Department of Neurology, Aldo Ravelli Research Center, University of Milan and ASST Saints Paul and Charles, Milan, Italy.
²² Department of Neurology, Faculty of Medicine and Cologne University Hospital, University of Cologne, Cologne, Germany.
²³ Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy.
²⁴ Department of Neurology and Neurosurgery, Institute of Clinical Medicine, Tartu, Estonia.
²⁵ Tartu University Hospital, Tartu, Estonia.
²⁶ Department of Neurology, Neuromed Campus, Kepler University Hospital, Linz, Austria.
²⁷ Medical Faculty, Johannes Kepler University, Linz, Austria.
²⁸ Neurology Unit, Neuromotor and Rehabilitation Department, USL-IRCCS Company of Reggio Emilia, Reggio Emilia, Italy.
²⁹ European Academy of Neurology Head Office, Vienna, Austria.
³⁰ Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
³¹ Department of Neurology, Mistelbach-Gänserndorf State Hospital, Mistelbach, Austria.

PMID: 35460319
PMCID: PMC9111566
DOI: 10.1111/ene.15368

Abstract

Background and purpose: Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course.

Methods: In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation.

Results: The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction.

Conclusions: The EAN NeuroCOVID-19 Task Force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals.

Keywords: COVID-19; SARS-CoV-2; advocacy; infectious disease prevention; neurological disorders; vaccination; vaccine skepticism.

PubMed Disclaimer

Conflict of interest statement

E.M. reports personal fees from sources outside the submitted work. The other authors have no conflict of interest to report.

Figures

See this image and copyright information in PMC

References

1. Sellner J, Jenkins TM, von Oertzen TJ, et al. Primary prevention of COVID‐19: advocacy for vaccination from a neurological perspective. Eur J Neurol. 2021;28(10):3226‐3229. - PubMed
1. Leidner AJ, Murthy N, Chesson HW, et al. Cost‐effectiveness of adult vaccinations: a systematic review. Vaccine. 2019;37(2):226‐234. - PMC - PubMed
1. Reddy KP, Fitzmaurice KP, Scott JA, et al. Clinical outcomes and cost‐effectiveness of COVID‐19 vaccination in South Africa. Nat Commun. 2021;12(1):6238. - PMC - PubMed
1. Lin DY, Gu Y, Wheeler B, et al. Effectiveness of covid‐19 vaccines over a 9‐month period in North Carolina. N Engl J Med. 2022;386(10):933‐941. - PMC - PubMed
1. Moreira ED Jr, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 covid‐19 vaccine. N Engl J Med. 2022;386(20):1910‐1921. doi:10.1056/NEJMoa2200674 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper

Affiliations

COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous